Published • loading... • Updated
Novo Nordisk Launches Wegovy Weight-Loss Pill in Germany
The oral semaglutide pill costs about €170 to €280 at retail and follows European Union approvals for use across the bloc.
- On Tuesday, Novo Nordisk launched its Wegovy pill in Germany, making it the first country in the 27-member European Union to offer the oral weight-loss treatment.
- Earlier this year, Novo introduced the pill in Britain, the United States, and the United Arab Emirates, utilizing semaglutide, the same active ingredient found in injectable Ozempic.
- Retail prices for the Wegovy pill range between €170 and €280 depending on dosage, while Novo estimated in August that the product captured 90% of the oral obesity market.
- Analysts expect the GLP-1 weight-loss business will reach more than $100 billion annually by 2030, intensifying competition as Novo faces pressure from Eli Lilly's Zepbound and Foundayo.
- Lilly's Foundayo is under regulatory review in more than 40 markets with a global rollout expected in 2027, as Novo predicts pills could comprise more than a third of total GLP-1 use by 2030.
Insights by Ground AI
26 Articles
26 Articles
Since September 1st, the diaphragm pill has been available in German pharmacies as an alternative to weight loss syringes. For whom the tablets are suitable and what needs to be taken into consideration.
BTReposted by 
Jyllands-Posten
Jyllands-PostenNovo Nordisk's weight loss pill has now been launched in the US, UK, United Arab Emirates and Germany.
·Borås, Sweden
Read Full Article
The Wegovy weight loss syringe gets competition from its own house: The active ingredient semaglutide is now also available as a tablet. Experts warn of a hype for the supposed miracle remedy. By Philipp Wundersee.
·Hamburg, Germany
Read Full Article
In Germany, wegovy is now also available as a tablet. What makes it different from the syringe? And what should be considered when taking it? The overview.
·Hamburg, Germany
Read Full ArticleCoverage Details
Total News Sources26
Leaning Left2Leaning Right8Center8Last UpdatedBias Distribution45% Center, 44% Right
Bias Distribution
- 45% of the sources are Center, 44% of the sources lean Right
45% Center
11%
C 45%
R 44%
Factuality
To view factuality data please Upgrade to Premium
